BioChimPharm has been included in the 2026 report of the European Bank for Reconstruction and Development (EBRD), which is dedicated to the global problem of antimicrobial resistance and approaches to addressing this crisis.

The excessive and irrational use of antibiotics leads to antimicrobial resistance (when antibiotics become ineffective against bacteria). Today, this problem causes approximately 1.3 million deaths worldwide each year, and by 2050 it is expected to exceed tens of millions if the same trend continues. At present, during this global challenge, bacteriophages (phages) are considered the only available and safe alternative to antibiotics. Unlike antibiotics, phages selectively destroy only harmful bacteria, including antibiotic-resistant strains, without damaging the beneficial microbiota in the human body.

In the report, Phagyo^® and the phage-producing company BioChimPharm are identified as making a significant contribution to the fight against antibiotic resistance. The document also highlights Georgia’s potential in the development of phage therapy.

The EBRD report places special emphasis on the modernization of BioChimPharm’s production facility in compliance with international GMP standards, which was implemented in 2023 with the support of the EBRD and other local and international partners. As part of the project, the world’s first phage production facility, founded in 1934, was upgraded and transformed into a high-tech biopharmaceutical manufacturing site compliant with international GMP standards.

According to the report, the modernization of the facility has enabled BioChimPharm to scale up production and further contribute to the development of phage therapy both in Georgia and in international markets.

“For us, as an EBRD partner in the fight against antimicrobial resistance, it is a great honor to receive such recognition for our journey. We are especially pleased that, with the support of the EBRD and our other partners, the world’s first phage production facility, founded in 1934, has been modernized and transformed into an innovative manufacturing site. This gives us the opportunity to bring GMP phages and phage therapy to even more patients and to contribute globally to addressing the challenge of antimicrobial resistance,” said Rati Golijashvii, General Manager of BioChimPharm.